An Unsuccessful Reach for the STELARA, Written description of generic biomolecule claims

by Harness, Dickey & Pierce, PLC

AbbVie owns US 6,914,128 (’128), which covers a variety of anti-IL12 monoclonal antibodies. AbbVie markets an anti-IL12 monoclonal (viz. Humira®) as a treatment for a variety of auto-immune disorders, including psoriasis. Centocor also markets an anti-IL12 monoclonal antibody (viz. Stelara®) for treating psoriasis. Claim 29 of ’128 claims “[a] neutralizing isolated human antibody, or antigen-binding portion thereof that binds to human IL-12 and disassociates from human IL-12 with a Koff rate constant of 1×10-2 s-1 or less, as determined by surface plasmon resonance.”

AbbVie sued Centocor for infringement of ’128 Claim 29. There was no dispute that Stelara® comes within the literal scope of ’128 Claim 29, so the trial mostly concerned validity. The U.S. District Court for the District of Massachusetts ruled that Claim 29 was invalid for lack of written description, lack of enablement, and obviousness. The Federal Circuit af?rmed the judgment, concluding speci?cally that Claim 29 lacked adequate written description.

Judge Lourie’s method of written description analysis was noteworthy for its clarity and incisiveness. He began his analysis by noting (slip op. at 22) that there are at least two sorts of disclosure that will satisfy the written description requirement when claiming a genus of biomolecules: “either [1] a representative number of species falling with the scope of the genus or [2] structural features common to the members of the genus so that one of skill in the art can ‘visualize or recognize’ the members of the genus” (quoting Univ. of Calif. v. Eli Lilly & Co., 119 F.3d 1559, 1568–69 (Fed. Cir. 1997)). AbbVie had admitted at trial that the ’128 speci?cation did not satisfy option 2, so the question on appeal was whether a reasonable jury could conclude from the facts of record that ’128 lacked disclosure of a representative number of species to support the generic claim.

The essence of the “representative number of species” approach is that the species disclosed must embody the full range of variation that exists within the claimed genus. It is not enough (slip op. at 23) just to “point out and distinctly circumscribe the outer boundaries of a claimed invention.” Rather, one must describe species suf?cient to show possession of the entire genus—not just one sub-genus within the broader genus. Judge Lourie reasoned (slip op. at 24 & 25) that because the asserted claim covers the allegedly infringing product, one must be able to ?nd at least one species described in the speci?cation that is structurally similar to the allegedly infringing product in order for Claim 29 to be supported by adequate written description.

Centocor had presented the jury with the following table, summarizing the structural differences between Stelara® and speci?c antibodies described in ’128 (viz. J695 and Joe-9). 7-3-2014 1-18-46 PMBecause written description is a question of fact, reviewed for substantial evidence, it was comparatively easy for the Federal Circuit to af?rm the jury’s verdict in view of this table of factual evidence.

Obviously the ’128 speci?cation disclosed possession of J695, whose CDRs were disclosed by amino acid sequence. It was hardly unreasonable, however, for the jury to conclude that the ’128 speci?cation did not convey possession of Stelara®. Although Judge Lourie was careful to note (slip op. at 25) that “AbbVie’s patents need not describe the allegedly infringing Stelara in exact terms…, the patents must at least describe some species representative of antibodies that are structurally similar to Stelara.” The jury had heard evidence that Stelara® had no more than 50% sequence similarity to the antibodies described in ’128, and that Stelara® used a different heavy-chain variable family and a different light chain type than any antibody described in ’128. In other words, there were signi?cant structural differences between Stelara® and the species described in ’128. Therefore, the Federal Circuit concluded that the jury’s verdict was supported by substantial evidence.

Judge O’Malley wrote a concurrence, opining that Judge Lourie’s written description analysis was all merely dicta. Judge O’Malley considered (slip op. at 2) that because AbbVie had not appealed the trial court’s conclusion of obviousness, the judgment below could be af?rmed on the uncontested obviousness grounds. Nevertheless, even if Judge Lourie’s opinion is mostly dicta, the written description analysis that he employed provides a more clear and simple approach to written description law that patent prosecutors and their clients should welcome. The complete opinion is available here.

Practice tip. MPEP §2163.II.A.3(a)(ii) says that “[t]he written description requirement for a claimed genus may be satis?ed through suf?cient description of a representative number of species…” Although the word “may” implies that there are other ways to satisfy the requirement, the quoted portion of the MPEP does not specify any. AbbVie v. Centocor helpfully reaf?rms that in addition to “representative number of species,” one can resolve a written description rejection by pointing to a description in the speci?cation of “structural features common to the members of the genus…”


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Harness, Dickey & Pierce, PLC | Attorney Advertising

Written by:

Harness, Dickey & Pierce, PLC

Harness, Dickey & Pierce, PLC on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.